Data & Analytics: New Frontiers for Big Data
Journal Ad Review: Paper Chase
Therapeutic Focus 2014: Metabolic
Specialty Pharma: Coverage at the Crossroads
MAHF 2014: Honoring Our Heroes
MM&M Awards: How to Win
Private View: Telling good brand stories
Read the complete 2014 MM&M Digital Guide digital edition
Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.
The newly titled Nurse Practitioner Perspective rolls out this month, keeping pace with an educational shift in the nursing field.
The issue: Boehringer's manufacturing site. The FDA is not asking for new clinical studies.
The drugmaker announced Tuesday that it will pursue a Phase-III Yervoy-nivolumab study.
Healthcare companies are partnering with social entrepreneurs to drive their own agendas on affordability and access while staying at the forefront of global initiatives
The drugmaker's annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.
Advocates say the National Institutes of Health is working with 22% less buying power than it had 11 years ago.
Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
The new MM&M e-book, "Oncology Marketing," is designed to serve as a companion for those in the business of communicating cancer products to all three stakeholders. It's packed with analysis, advice, insights and commentary to help navigate the terrain. Click here to access it.